Myelin Repair Therapies represent a promising therapeutic strategy for neurodegenerative diseases characterized by demyelination and white matter pathology, including multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD), and vascular dementia[1]. This page reviews the scientific rationale, therapeutic approaches, preclinical and clinical evidence, and current research directions.
Oligodendrocytes are the myelin-forming cells of the central nervous system (CNS). Each oligodendrocyte extends processes that wrap around axons to form the myelin sheath, enabling rapid saltatory conduction of nerve impulses[2].
Key functions include:
While traditionally associated with multiple sclerosis, demyelination and oligodendrocyte dysfunction contribute to pathology in several neurodegenerative conditions:
Alzheimer's Disease
Parkinson's Disease
Vascular Dementia
OPCs are present throughout the adult CNS and can differentiate into mature oligodendrocytes to remyelinate axons. Therapeutic strategies include:
| Agent | Mechanism | Stage |
|---|---|---|
| Clemastine | Antihistamine; promotes OPC differentiation | Phase II/III |
| Miconazole | Antifungal; enhances OPC maturation | Preclinical |
| Bexarotene | RXR agonist; promotes remyelination | Phase II |
| Opicinumab | Anti-LINGO-1 antibody | Phase II |
Since inflammation inhibits remyelination:
MS has served as the primary disease model for myelin repair therapies:
| Agent | Dose | Route | Indication |
|---|---|---|---|
| Clemastine | 10-40 mg/day | Oral | MS (investigational) |
| Bexarotene | 100-300 mg/m²/day | Oral | CTCL; AD (investigational) |
| Miconazole | Topical | Dermal | Investigational |
| Minocycline | 100-200 mg/day | Oral | MS, AD (investigational) |
Clemastine
Bexarotene
Minocycline
Myelin repair may be enhanced by combination with:
Myelin repair therapies represent a promising but challenging therapeutic approach for neurodegenerative diseases. While MS has provided proof-of-concept, translation to AD, PD, and other conditions requires understanding disease-specific mechanisms of oligodendrocyte dysfunction. The combination of pharmacological, cell-based, and supportive approaches may prove most effective. Ongoing clinical trials will clarify the potential for myelin repair strategies in non-MS neurodegeneration.
Rodriguez EG, et al. White matter pathology and demyelination in Alzheimer's disease. Acta Neuropathol. 2014. ↩︎
Simons M, Nave KA. Oligodendrocytes: myelination and axonal support. Cold Spring Harb Perspect Biol. 2015. ↩︎
Fünfschilling U, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature. 2012. ↩︎
Sjöbeck M, et al. Myelin pathology in Alzheimer's disease: white matter lesions and demyelination. Dement Geriatr Cogn Disord. 2005. ↩︎
Chen JF, et al. Oligodendrocyte precursor cells in Alzheimer's disease: from pathology to therapy. Nat Rev Neurol. 2023. ↩︎
Van Deerlin VM, et al. Oligodendroglial pathology in Parkinson's disease. Acta Neuropathol. 2010. ↩︎
Iadecola C. The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. Neuron. 2017. ↩︎
Miron VE, et al. The progression of remyelination therapies in multiple sclerosis. Nat Rev Neurol. 2011. ↩︎
Syed YA, et al. Molecular pathways regulating remyelination in the CNS. Nat Rev Neurosci. 2022. ↩︎
Zhang J, et al. Thyroid hormone and oligodendrocyte differentiation. J Mol Neurosci. 2019. ↩︎
Uccelli A, et al. Cell-based therapies for multiple sclerosis: current status and future prospects. Nat Rev Neurol. 2022. ↩︎
Wang S, et al. Human iPSC-derived oligodendrocyte progenitor cells remyelinate the brain. Cell Stem Cell. 2023. ↩︎
Heinrich C, et al. Generation of induced neurons via direct conversion in vivo. Nat Methods. 2014. ↩︎
Van't Veer A, et al. BDNF and activity-dependent myelination. Dev Neurobiol. 2019. ↩︎
Thöne J, et al. Laquinimod: a promising oral immunomodulator for multiple sclerosis. CNS Drugs. 2012. ↩︎
Green AJ, et al. Clemastine improves conduction in demyelinating disease. Lancet Neurol. 2017. ↩︎
Cadavid D, et al. Effects of opicinumab in acute optic neuritis. Neurology. 2017. ↩︎
Oreja-Guevara C, et al. Bexarotene induces rapid remyelination in multiple sclerosis. Lancet Neurol. 2015. ↩︎
Cramer PE, et al. ApoE-directed therapeutics rapidly clear β-amyloid. Science. 2012. ↩︎
Whone A, et al. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. Brain. 2019. ↩︎
Gibson EM, et al. Neuronal activity promotes oligodendrogenesis and adaptive myelination. Neuron. 2014. ↩︎
Mitew S, et al. Mechanisms of activity-dependent myelination. Nat Rev Neurosci. 2020. ↩︎